Patent intelligence · US
US 6201129
Tricyclic derivatives and their use as anti-cancer agents
Tricyclic derivatives and their use as anti-cancer agents
Patent details — US 6201129
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 13, 2001
- Expiration
- Mar 8, 2021
- Applicant
- Univ. College Cardiff Consultants
- Claims
- 11
- CPC classes
- A61P, A61P35/00
Quick answer
US 6201129 (Tricyclic derivatives and their use as anti-cancer agents) is held by Univ. College Cardiff Consultants. Status: expired. Granted Mar 13, 2001. Expires Mar 8, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Univ. College Cardiff Consultants
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P35/00
More from Univ. College Cardiff Consultants
Related pharmaceutical patents in our USPTO index.
-
US 12383540
Compounds that modulates AMPA receptor function
granted -
US 12318418
Modified adenoviruses
granted -
US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12053513
Cancer-specific T-cell receptors
granted -
US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
granted -
US 11850264
Gamma delta T-cell receptor and its ligand
granted -
US 11725039
α/β t-cell receptor and methods of using it
granted
Frequently asked questions
What is US patent 6201129?
US 6201129 (Tricyclic derivatives and their use as anti-cancer agents) is held by Univ. College Cardiff Consultants. Status: expired. Granted Mar 13, 2001. Expires Mar 8, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6201129?
Univ. College Cardiff Consultants is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 6201129 expire?
Our index shows an expiration date of Mar 8, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.